1h Free Analyst Time
According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Drugs In Development, 2021'; Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. Speak directly to the analyst to clarify any post sales queries you may have.
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Gamma-aminobutyric acid A receptor, alpha 5 or GABRA5 is a protein encoded by the GABRA5 gene. It mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
The report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Drugs In Development, 2021' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 4 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Genetic Disorders which include indications Cognitive Disorders, Schizophrenia, Alzheimer's Disease, Anxiety Disorders, Autism, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Down Syndrome, Epilepsy, Ischemic Stroke, Mild Cognitive Impairment, Panic Disorders, Pervasive Developmental Disorder (PDD) and Traumatic Brain Injury.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)
- The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionGamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Overview
- Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- AgeneBio Inc
- Cerevel Therapeutics Holdings Inc
- F. Hoffmann-La Roche Ltd
- Les Laboratoires Servier SAS
- Ono Pharmaceutical Co Ltd
- Saniona AB
- afizagabar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AGB-473 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AVL-8168 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- basmisanil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- darigabat - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ONO-8590580 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RG-7816 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RO-4938581 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Agonize GABRA5 for Schizophrenia and Autism - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Antagonise GABRA5 for Cognitive Impairment - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Antagonize GABRA5 for Depression - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Dormant Products
Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Product Development Milestones
Featured News & Press Releases
- Jan 28, 2021: Cerevel Therapeutics hosts Inaugural Virtual R&D event to review Darigabat (CVL-865) and provide overview of key preclinical programs
- Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigational therapy in development for the treatment of Epilepsy
- Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel a2/3/5-subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy
- Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865
- Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigational Epilepsy treatment
- Oct 09, 2018: AgeneBio Announces NIH grant award to support development of GABA-A a5 small molecule program targeting hippocampal overactivity
- Jul 12, 2018: Saniona receives milestone payment from Boehringer Ingelheim
- Sep 13, 2017: AgeneBio to Receive up to $10 Million in NIH Funding to Advance Program for Mild Cognitive Impairment Due to Alzheimer’s Disease
- Jun 30, 2017: AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for Drug-Discovery Program to Delay the Onset of Alzheimer’s Dementia
- Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome
- Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2021
- Number of Products under Development by Therapy Areas, 2021
- Number of Products under Development by Indication, 2021
- Number of Products under Development by Companies, 2021
- Products under Development by Companies, 2021
- Number of Products under Investigation by Universities/Institutes, 2021
- Products under Investigation by Universities/Institutes, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
- Pipeline by AgeneBio Inc, 2021
- Pipeline by Cerevel Therapeutics Holdings Inc, 2021
- Pipeline by F. Hoffmann-La Roche Ltd, 2021
- Pipeline by Les Laboratoires Servier SAS, 2021
- Pipeline by Ono Pharmaceutical Co Ltd, 2021
- Pipeline by Saniona AB, 2021
- Dormant Projects, 2021
- Discontinued Products, 2021
List of Figures
- Number of Products under Development by Stage of Development, 2021
- Number of Products under Development by Therapy Areas, 2021
- Number of Products under Development by Top 10 Indications, 2021
- Number of Products by Mechanism of Actions, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AgeneBio Inc
- Cerevel Therapeutics Holdings Inc
- F. Hoffmann-La Roche Ltd
- Les Laboratoires Servier SAS
- Ono Pharmaceutical Co Ltd
- Saniona AB
